Gilead Sciences, Inc.
์๊ฐ์ด์ก
$177.9B
๊ธ๋ก๋ฒ ์์
#95
์ญ๋ ์ต๊ณ ์น
$177.9B
2026-08-18
์ด ์ฑ์ฅ๋ฅ
+0%
2026๋ ์ดํ
Market Cap Context
- Larger than 74% of the 367 companies we track (globally).
- Equivalent to 0.6% of United States's GDP (2025 data).
- Just above: #94 BlackRock, Inc. ($178.8B)
- Just below: #96 ์ ๋์ธ ํผ์ํฝ ($177.5B)
- Best year: 1995 (+237%). Worst year: 2016 (-28%).
Gilead Sciences, Inc. Financial Breakdown (FY 2025)
Source: Yahoo Finance โ GILD annual filings (2025) โ$29.4B revenue ยท $11.7B operating income ยท $8.5B net income
- โOperating margin: 39.7% on $29.4B in revenue.
- โR&D is 19.7% of revenue ($5.8B).
- โNet income margin: 28.9% โ $8.5B in profit.
- โFree cash flow: $9.5B (32.1% of revenue).
Cost / Operating Expenses
Total operating expenses $17.7B
Total
$17.7B
Capital Expenditures
$0.6B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$9.5B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Gilead Sciences, Inc. ์๊ฐ
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Gilead Sciences, Inc. ์๊ฐ์ด์ก ์ถ์ด (2026โ2026)
Gilead Sciences, Inc. vs Sector Peers by Market Cap
Gilead Sciences, Inc. ๋น๊ต
์์ ์ถ์ด
| ์ฐ๋ | ์๊ฐ์ด์ก | ์์ | ์ ๋ ๋๋น ๋ณํ |
|---|---|---|---|
| 2026 | $177.9B | #95(โ13) | +18.2% |
| 2025 | $150.5B | #108(โ14) | +36.8% |
| 2024 | $110.0B | #122 | +18.8% |
| 2023 | $92.6B | #122(โ21) | -2.1% |
| 2022 | $94.6B | #101(โ27) | +23.9% |
| 2021 | $76.4B | #128(โ19) | +30.1% |
| 2020 | $58.7B | #147(โ39) | -6.9% |
| 2019 | $63.0B | #108(โ21) | +7.8% |
| 2018 | $58.5B | #87(โ7) | -10.1% |
| 2017 | $65.0B | #80(โ17) | +2.9% |
| 2016 | $63.2B | #63(โ27) | -27.7% |
| 2015 | $87.4B | #36(โ5) | +8.2% |
| 2014 | $80.8B | #41(โ6) | +25.5% |
| 2013 | $64.4B | #47(โ34) | +104.5% |
| 2012 | $31.5B | #81(โ39) | +79.5% |
| 2011 | $17.6B | #120(โ23) | +12.9% |
| 2010 | $15.5B | #143(โ33) | -16.2% |
| 2009 | $18.6B | #110(โ48) | -15.4% |
| 2008 | $21.9B | #62(โ50) | +11.1% |
| 2007 | $19.7B | #112(โ29) | +41.7% |
| 2006 | $13.9B | #141(โ3) | +23.5% |
| 2005 | $11.3B | #138(โ21) | +50.2% |
| 2004 | $7.5B | #159(โ4) | +20.1% |
| 2003 | $6.2B | #155(โ13) | +71.4% |
| 2002 | $3.6B | #168(โ20) | +3.5% |
| 2001 | $3.5B | #188(โ5) | +58.5% |
| 2000 | $2.2B | #193(โ23) | +53.2% |
| 1999 | $1.5B | #170(โ9) | +31.8% |
| 1998 | $1.1B | #161(โ5) | +7.4% |
| 1997 | $1.0B | #156 | +53.0% |
| 1996 | $670.1M | #156(โ18) | -21.9% |
| 1995 | $857.7M | #138(โ4) | +236.8% |
| 1994 | $254.6M | #134 |
๊ธฐํ ํฌ์ค์ผ์ด ๊ธฐ์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
What is Gilead Sciences, Inc.'s market cap?
Gilead Sciences, Inc. (GILD) has a market capitalization of $177.9B, making it the #95 largest company in the world by market cap.
What was Gilead Sciences, Inc.'s highest market cap?
Gilead Sciences, Inc.'s all-time high market cap was $177.9B, reached in 2026-08-18. Its highest rank was #95 in 2026.
What sector is Gilead Sciences, Inc. in?
Gilead Sciences, Inc. is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.
How has Gilead Sciences, Inc.'s market cap changed over time?
Gilead Sciences, Inc. has been tracked since 2026. Its market cap has grown by 0% from $177.9B in 2026 to $177.9B today.